NCOA1

2 papers4 findings

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

A gene’s or a process’s line counts the gene with the processes named after it, as NLRP3 with the NLRP3 inflammasome, and the trials of drugs aimed at it.

1 lab in 1 country

Funders: Agence Nationale de la Recherche and 5 more

Humans1
Cells1

Effects

Glucose intolerance

downin mice1

1 study

NCOA1 protects against glucose intolerance in mice.
“Female mice lacking this coregulator progressively developed obesity and glucose intolerance”
Animalsshown by knockoutfemales
NCOA1 is a gatekeeper of the sexually dimorphic thermogenic activity of white adipose tissue
Nature communications20 Jan 2026